Day One Biopharmaceuticals, Inc. (DAWN)
Form 4 sales, Form 144 notices and lockup dates
- Latest sale
- $179k
- Feb 17 · No plan
- Form 4 sales
- 127
- On record
- Form 144 notices
- 8
- Proposed sales
- Next unlock
- None
- No lockup ahead
Lockups
No lockup on record.
Sales by reason
Timeline
- 1 Form 4 saleNo planNov 17 2025
Sold 4,319 shares at $8.91 ($38k)
Dubow Adam, Gen Counsel & Secretary
No 10b5-1 planSold 6.5% of holdings ($596k position)62,626 shares left1.3x usual sizeFiling
- 2 Form 4 saleNo planNov 17 same day
Sold 3,726 shares at $8.91 ($33k)
Merendino Lauren, Chief Commercial Officer
No 10b5-1 planSold 6.8% of holdings ($486k position)50,809 shares leftFiling
- 3 Form 4 saleNo planNov 17 same day
Sold 15,894 shares at $8.91 ($142k)
Bender Jeremy, CHIEF EXECUTIVE OFFICER
No 10b5-1 planSold 8.2% of holdings ($1.7M position)177,165 shares left1.4x usual sizeFiling
- 4 Form 4 saleNo planFeb 17 +92 days
Sold 6,065 shares at $11.60 ($70k)
York Charles N II, COO and CFO
No 10b5-1 planSold 1.9% of holdings ($3.7M position)312,025 shares left1.5x usual sizeFiling
- 5 Form 4 saleUnusualFeb 17 same day
Sold 2,728 shares at $11.60 ($32k)
Vasconcelles Michael, Head of Research and Dev.
No 10b5-1 planSold 38.3% of holdings ($83k position)4,397 shares leftFirst sale on recordFiling
- 6 Form 4 saleNo planFeb 17 same day
Sold 6,395 shares at $11.60 ($74k)
Dubow Adam, Gen Counsel & Secretary
No 10b5-1 planSold 8.1% of holdings ($917k position)72,694 shares left1.5x usual sizeFiling
- 7 Form 4 saleNo planFeb 17 same day
Sold 5,814 shares at $11.60 ($67k)
Merendino Lauren, Chief Commercial Officer
No 10b5-1 planSold 8.8% of holdings ($765k position)60,157 shares left1.5x usual sizeFiling
- 8 Form 4 saleNo planFeb 17 same day
Sold 15,459 shares at $11.60 ($179k)
Bender Jeremy, CHIEF EXECUTIVE OFFICER
No 10b5-1 planSold 7% of holdings ($2.6M position)204,603 shares left1.2x usual sizeFiling
Every transaction
Loading transactions…
Sales, notices and lockups (135)
Export watchlist as CSV| Source | ||||||||
|---|---|---|---|---|---|---|---|---|
| Feb 17, 2026 | Bender Jeremy | CHIEF EXECUTIVE OFFICER | Form 4 sale | 15,459 | $179k | 7.0% | No plan | SEC |
| Feb 17, 2026 | Merendino Lauren | Chief Commercial Officer | Form 4 sale | 5,814 | $67k | 8.8% | No plan | SEC |
| Feb 17, 2026 | Dubow Adam | Gen Counsel & Secretary | Form 4 sale | 6,395 | $74k | 8.1% | No plan | SEC |
| Feb 17, 2026 | Vasconcelles Michael | Head of Research and Dev. | Form 4 sale | 2,728 | $32k | 38.3% | Unusual | SEC |
| Feb 17, 2026 | York Charles N II | COO and CFO | Form 4 sale | 6,065 | $70k | 1.9% | No plan | SEC |
| Nov 17, 2025 | Bender Jeremy | CHIEF EXECUTIVE OFFICER | Form 4 sale | 15,894 | $142k | 8.2% | No plan | SEC |
| Nov 17, 2025 | Merendino Lauren | Chief Commercial Officer | Form 4 sale | 3,726 | $33k | 6.8% | No plan | SEC |
| Nov 17, 2025 | Dubow Adam | Gen Counsel & Secretary | Form 4 sale | 4,319 | $38k | 6.5% | No plan | SEC |
| Nov 17, 2025 | York Charles N II | COO and CFO | Form 4 sale | 4,062 | $36k | 1.4% | No plan | SEC |
| Aug 18, 2025 | York Charles N II | COO and CFO | Form 4 sale | 4,106 | $28k | 1.5% | No plan | SEC |
| Aug 18, 2025 | Dubow Adam | Gen Counsel & Secretary | Form 4 sale | 4,365 | $30k | 7.4% | No plan | SEC |
| Aug 18, 2025 | Bender Jeremy | CHIEF EXECUTIVE OFFICER | Form 4 sale | 16,058 | $109k | 9.1% | No plan | SEC |
| Aug 18, 2025 | Merendino Lauren | Chief Commercial Officer | Form 4 sale | 3,766 | $25k | 8.2% | No plan | SEC |
| May 16, 2025 | Merendino Lauren | Chief Commercial Officer | Form 4 sale | 3,927 | $25k | 10.0% | No plan | SEC |
| May 16, 2025 | Dubow Adam | GENERAL COUNSEL | Form 4 sale | 4,552 | $28k | 8.8% | No plan | SEC |
| May 16, 2025 | York Charles N II | COO, CFO AND SECRETARY | Form 4 sale | 4,282 | $27k | 1.6% | No plan | SEC |
| May 16, 2025 | Bender Jeremy | CHIEF EXECUTIVE OFFICER | Form 4 sale | 13,964 | $87k | 8.7% | No plan | SEC |
| Feb 18, 2025 | York Charles N II | COO, CFO AND SECRETARY | Form 4 sale | 4,370 | $52k | 1.7% | No plan | SEC |
| Feb 18, 2025 | Dubow Adam | GENERAL COUNSEL | Form 4 sale | 4,646 | $56k | 10.5% | No plan | SEC |
| Feb 18, 2025 | Bender Jeremy | CHIEF EXECUTIVE OFFICER | Form 4 sale | 12,048 | $144k | 8.6% | No plan | SEC |
| Dec 10, 2024 | Blackman Samuel C. | HEAD OF R&D | Form 4 sale | 30,000 | $399k | 2.8% | Unusual | SEC |
| Nov 18, 2024 | Bender Jeremy | CHIEF EXECUTIVE OFFICER | Form 4 sale | 10,554 | $139k | 8.9% | No plan | SEC |
| Nov 18, 2024 | Blackman Samuel C. | HEAD OF R&D | Form 4 sale | 2,206 | $29k | 0.2% | No plan | SEC |
| Nov 18, 2024 | Dubow Adam | GENERAL COUNSEL | Form 4 sale | 3,165 | $42k | 9.0% | No plan | SEC |
| Nov 18, 2024 | York Charles N II | COO, CFO AND SECRETARY | Form 4 sale | 2,602 | $34k | 1.1% | No plan | SEC |
| Nov 11, 2024 | Blackman Samuel C. | HEAD OF R&D | Form 4 sale | 28,255 | $456k | 2.6% | Routine | SEC |
| Nov 7, 2024 | Blackman Samuel C. | HEAD OF R&D | Form 4 sale | 11,245 | $180k | 1.0% | Routine | SEC |
| Oct 31, 2024 | Blackman Samuel C. | HEAD OF R&D | Form 4 sale | 500 | $8k | 0.0% | Routine | SEC |
| Sep 10, 2024 | Blackman Samuel C. | HEAD OF R&D | Form 4 sale | 30,000 | $427k | 2.7% | Unusual | SEC |
| Aug 16, 2024 | Dubow Adam | GENERAL COUNSEL | Form 4 sale | 3,202 | $45k | 10.6% | No plan | SEC |
| Aug 16, 2024 | York Charles N II | COO, CFO AND SECRETARY | Form 4 sale | 2,633 | $37k | 1.1% | No plan | SEC |
| Aug 16, 2024 | Blackman Samuel C. | HEAD OF R&D | Form 4 sale | 2,232 | $31k | 0.2% | No plan | SEC |
| Aug 16, 2024 | Bender Jeremy | CHIEF EXECUTIVE OFFICER | Form 4 sale | 10,681 | $150k | 9.7% | No plan | SEC |
| Jul 16, 2024 | Blackman Samuel C. | HEAD OF R&D | Form 4 sale | 20,000 | $320k | 1.8% | Routine | SEC |
| Jun 21, 2024 | Ramasastry Saira | Director | Form 4 sale | 10,000 | $132k | 19.8% | No plan | SEC |
| Jun 10, 2024 | Blackman Samuel C. | HEAD OF R&D | Form 4 sale | 30,000 | $379k | 2.6% | Unusual | SEC |
| May 16, 2024 | Bender Jeremy | CHIEF EXECUTIVE OFFICER | Form 4 sale | 7,873 | $127k | 1.2% | No plan | SEC |
| May 16, 2024 | Blackman Samuel C. | HEAD OF R&D | Form 4 sale | 2,267 | $36k | 0.2% | No plan | SEC |
| May 16, 2024 | York Charles N II | COO, CFO AND SECRETARY | Form 4 sale | 2,675 | $43k | 1.2% | No plan | SEC |
| May 16, 2024 | Dubow Adam | GENERAL COUNSEL | Form 4 sale | 3,253 | $52k | 13.0% | No plan | SEC |
| May 10, 2024 | Blackman Samuel C. | HEAD OF R&D | Form 4 sale | 10,000 | $164k | 0.9% | Routine | SEC |
| May 3, 2024 | Bender Jeremy | CHIEF EXECUTIVE OFFICER | Form 4 sale | 79,211 | $1.4M | 11.0% | Unusual | SEC |
| May 3, 2024 | York Charles N II | COO, CFO AND SECRETARY | Form 4 sale | 60,461 | $1.1M | 21.8% | Unusual | SEC |
| Apr 18, 2024 | Blackman Samuel C. | HEAD OF R&D | Form 4 sale | 10,000 | $160k | 0.8% | Routine | SEC |
| Mar 25, 2024 | Blackman Samuel C. | HEAD OF R&D | Form 4 sale | 10,000 | $160k | 0.8% | Routine | SEC |
| Mar 11, 2024 | Blackman Samuel C. | HEAD OF R&D | Form 4 sale | 30,000 | $457k | 2.4% | Unusual | SEC |
| Feb 27, 2024 | Blackman Samuel C. | HEAD OF R&D | Form 4 sale | 20,000 | $322k | 1.6% | Routine | SEC |
| Feb 27, 2024 | Blackman Samuel C. | Officer | Form 144 notice | 80,000 | $1.3M | Notice | SEC | |
| Feb 16, 2024 | Dubow Adam | GENERAL COUNSEL | Form 4 sale | 3,242 | $49k | 16.4% | No plan | SEC |
| Feb 16, 2024 | York Charles N II | COO, CFO AND SECRETARY | Form 4 sale | 2,666 | $41k | 1.0% | No plan | SEC |
| Feb 16, 2024 | Blackman Samuel C. | HEAD OF RESEARCH AND DEVELOPME | Form 4 sale | 2,258 | $34k | 0.2% | No plan | SEC |
| Feb 16, 2024 | Bender Jeremy | CHIEF EXECUTIVE OFFICER | Form 4 sale | 7,615 | $116k | 1.0% | No plan | SEC |
| Feb 16, 2024 | Bender Jeremy | Officer, Director | Form 144 notice | 7,615 | $116k | Notice | SEC | |
| Nov 16, 2023 | York Charles N II | COO, CFO and Secretary | Form 4 sale | 956 | $11k | 0.4% | No plan | SEC |
| Nov 16, 2023 | Dubow Adam | General Counsel | Form 4 sale | 5,313 | $62k | 31.7% | Unusual | SEC |
| Nov 16, 2023 | Blackman Samuel C. | Head of Research and Developme | Form 4 sale | 709 | $8k | 0.1% | No plan | SEC |
| Nov 16, 2023 | Bender Jeremy | Chief Executive Officer | Form 4 sale | 3,107 | $36k | 0.4% | No plan | SEC |
| Nov 16, 2023 | Bender Jeremy | Officer, Director | Form 144 notice | 3,107 | $36k | Notice | SEC | |
| Nov 16, 2023 | Dubow Adam | Officer | Form 144 notice | 5,313 | $62k | Notice | SEC | |
| Aug 17, 2023 | York Charles N II | COO, CFO and Secretary | Form 4 sale | 922 | $13k | 0.3% | No plan | SEC |
| Aug 17, 2023 | Blackman Samuel C. | Head of Research and Developme | Form 4 sale | 668 | $9k | 0.1% | No plan | SEC |
| Aug 17, 2023 | Bender Jeremy | Chief Executive Officer | Form 4 sale | 2,996 | $42k | 0.4% | No plan | SEC |
| Jun 5, 2023 | Blackman Samuel C. | Chief Medical Officer | Form 4 sale | 1,229 | $20k | 0.1% | No plan | SEC |
| Jun 5, 2023 | Blackman Samuel C. | Officer | Form 144 notice | 10,000 | $136k | Notice | SEC | |
| May 16, 2023 | York Charles N II | COO, CFO and Secretary | Form 4 sale | 955 | $13k | 0.4% | No plan | SEC |
| May 16, 2023 | Blackman Samuel C. | Chief Medical Officer | Form 4 sale | 692 | $9k | 0.1% | No plan | SEC |
| May 16, 2023 | Bender Jeremy | Chief Executive Officer | Form 4 sale | 3,104 | $41k | 0.3% | No plan | SEC |
| May 16, 2023 | Blackman Samuel C. | Officer | Form 144 notice | 692 | $9k | Notice | SEC | |
| May 16, 2023 | York Charles N II | Officer | Form 144 notice | 955 | $13k | Notice | SEC | |
| May 16, 2023 | Bender Jeremy | Officer, Director | Form 144 notice | 3,104 | $41k | Notice | SEC | |
| Mar 10, 2023 | Blackman Samuel C. | Chief Medical Officer | Form 4 sale | 10,000 | $181k | 0.8% | Plan not stated | SEC |
| Mar 7, 2023 | Bender Jeremy | Chief Executive Officer | Form 4 sale | 12,500 | $250k | 1.1% | Plan not stated | SEC |
| Mar 1, 2023 | Grant Julie Papanek | Director | Form 4 sale | 25,000 | $465k | 7.0% | Plan not stated | SEC |
| Feb 17, 2023 | York Charles N II | COO, CFO and Secretary | Form 4 sale | 9,377 | $188k | 3.5% | Plan not stated | SEC |
| Feb 16, 2023 | York Charles N II | COO, CFO and Secretary | Form 4 sale | 930 | $18k | 0.3% | Plan not stated | SEC |
| Feb 16, 2023 | Blackman Samuel C. | Chief Medical Officer | Form 4 sale | 674 | $13k | 0.1% | Plan not stated | SEC |
| Feb 16, 2023 | Bender Jeremy | Chief Executive Officer | Form 4 sale | 3,022 | $59k | 0.3% | Plan not stated | SEC |
| Feb 10, 2023 | Blackman Samuel C. | Chief Medical Officer | Form 4 sale | 10,000 | $201k | 0.8% | Plan not stated | SEC |
| Feb 1, 2023 | Grant Julie Papanek | Director | Form 4 sale | 25,000 | $531k | 6.6% | Plan not stated | SEC |
| Jan 23, 2023 | Bender Jeremy | Chief Executive Officer | Form 4 sale | 12,500 | $275k | 1.0% | Plan not stated | SEC |
| Jan 20, 2023 | York Charles N II | COO, CFO and Secretary | Form 4 sale | 10,000 | $228k | 3.6% | Plan not stated | SEC |
| Jan 10, 2023 | Blackman Samuel C. | Chief Medical Officer | Form 4 sale | 10,000 | $229k | 0.8% | Plan not stated | SEC |
| Jan 3, 2023 | Grant Julie Papanek | Director | Form 4 sale | 25,000 | $516k | 6.2% | Plan not stated | SEC |
| Dec 21, 2022 | Bender Jeremy | Chief Executive Officer | Form 4 sale | 12,500 | $254k | 1.0% | Plan not stated | SEC |
| Dec 20, 2022 | York Charles N II | COO, CFO and Secretary | Form 4 sale | 10,000 | $201k | 3.5% | Plan not stated | SEC |
| Dec 8, 2022 | Grant Julie Papanek | Director | Form 4 sale | 4,358 | $96k | 1.1% | Plan not stated | SEC |
| Dec 2, 2022 | Grant Julie Papanek | Director | Form 4 sale | 10,000 | $216k | 2.4% | Plan not stated | SEC |
| Dec 1, 2022 | Blackman Samuel C. | Chief Medical Officer | Form 4 sale | 10,000 | $215k | 0.8% | Plan not stated | SEC |
| Nov 21, 2022 | York Charles N II | COO, CFO and Secretary | Form 4 sale | 10,000 | $208k | 3.4% | Unusual | SEC |
| Nov 21, 2022 | Bender Jeremy | Chief Executive Officer | Form 4 sale | 12,500 | $260k | 1.0% | Plan not stated | SEC |
| Nov 16, 2022 | York Charles N II | COO, CFO and Secretary | Form 4 sale | 430 | $9k | 0.1% | Plan not stated | SEC |
| Nov 16, 2022 | Blackman Samuel C. | Chief Medical Officer | Form 4 sale | 377 | $8k | 0.0% | Plan not stated | SEC |
| Nov 16, 2022 | Bender Jeremy | Chief Executive Officer | Form 4 sale | 1,513 | $32k | 0.1% | Plan not stated | SEC |
| Nov 2, 2022 | Grant Julie Papanek | Director | Form 4 sale | 10,000 | $200k | 2.3% | Plan not stated | SEC |
| Nov 1, 2022 | York Charles N II | COO, CFO and Secretary | Form 4 sale | 10,000 | $200k | 3.3% | Unusual | SEC |
| Nov 1, 2022 | Blackman Samuel C. | Chief Medical Officer | Form 4 sale | 10,000 | $200k | 0.8% | Plan not stated | SEC |
| Nov 1, 2022 | Bender Jeremy | Chief Executive Officer | Form 4 sale | 12,500 | $250k | 1.0% | Plan not stated | SEC |
| Oct 4, 2022 | Grant Julie Papanek | Director | Form 4 sale | 10,000 | $200k | 2.3% | Plan not stated | SEC |
| Oct 3, 2022 | York Charles N II | COO, CFO and Secretary | Form 4 sale | 10,000 | $201k | 3.2% | Unusual | SEC |
| Oct 3, 2022 | Blackman Samuel C. | Chief Medical Officer | Form 4 sale | 10,000 | $200k | 0.8% | Plan not stated | SEC |
| Oct 3, 2022 | Bender Jeremy | Chief Executive Officer | Form 4 sale | 12,500 | $251k | 1.0% | Unusual | SEC |
| Sep 21, 2022 | Canaan XI L.P. | 10% owner | Form 4 sale | 613,603 | $11.4M | 6.8% | Plan not stated | SEC |
| Sep 21, 2022 | Grant Julie Papanek | Director | Form 4 sale | 613,603 | $11.4M | 6.8% | Unusual | SEC |
| Sep 20, 2022 | Grant Julie Papanek | Director | Form 4 sale | 340,702 | $7M | 3.6% | Unusual | SEC |
| Sep 20, 2022 | Canaan Partners XI LLC | 10% owner | Form 4 sale | 340,702 | $7M | 3.6% | Plan not stated | SEC |
| Sep 15, 2022 | Grant Julie Papanek | Director | Form 4 sale | 245,039 | $5.8M | 2.5% | Unusual | SEC |
| Sep 15, 2022 | Canaan Partners XI LLC | 10% owner | Form 4 sale | 245,039 | $5.8M | 2.5% | Plan not stated | SEC |
| Sep 2, 2022 | Grant Papanek Julie | Director | Form 4 sale | 5,000 | $119k | 1.1% | Plan not stated | SEC |
| Sep 1, 2022 | York Charles N II | COO, CFO and Secretary | Form 4 sale | 10,000 | $232k | 3.1% | Unusual | SEC |
| Sep 1, 2022 | Grant Papanek Julie | Director | Form 4 sale | 5,000 | $116k | 1.1% | Plan not stated | SEC |
| Sep 1, 2022 | Blackman Samuel C. | Chief Medical Officer | Form 4 sale | 10,000 | $232k | 0.8% | Plan not stated | SEC |
| Sep 1, 2022 | Bender Jeremy | Chief Executive Officer | Form 4 sale | 12,500 | $291k | 1.0% | Unusual | SEC |
| Sep 1, 2022 | Bender Jeremy | Chief Executive Officer | Form 4 sale | 12,500 | $291k | 1.0% | Unusual | SEC |
| Aug 16, 2022 | Blackman Samuel C. | Chief Medical Officer | Form 4 sale | 941 | $23k | 0.1% | Plan not stated | SEC |
| Aug 16, 2022 | Bender Jeremy | Chief Executive Officer | Form 4 sale | 4,003 | $97k | 0.3% | Plan not stated | SEC |
| Aug 16, 2022 | York Charles N II | COO, CFO and Secretary | Form 4 sale | 1,089 | $26k | 0.3% | Plan not stated | SEC |
| Aug 5, 2022 | Grant Papanek Julie | Director | Form 4 sale | 10,000 | $200k | 2.2% | Unusual | SEC |
| Aug 4, 2022 | York Charles N II | COO, CFO and Secretary | Form 4 sale | 10,000 | $201k | 3.0% | Unusual | SEC |
| Aug 4, 2022 | Bender Jeremy | Chief Executive Officer | Form 4 sale | 12,500 | $250k | 1.0% | Unusual | SEC |
| Aug 1, 2022 | Blackman Samuel C. | Chief Medical Officer | Form 4 sale | 10,000 | $169k | 0.8% | Plan not stated | SEC |
| Jul 18, 2022 | York Charles N II | COO, CFO and Secretary | Form 4 sale | 2,500 | $50k | 0.7% | Plan not stated | SEC |
| Jul 18, 2022 | Grant Papanek Julie | Director | Form 4 sale | 2,600 | $52k | 0.6% | Plan not stated | SEC |
| Jul 18, 2022 | Bender Jeremy | Chief Executive Officer | Form 4 sale | 2,600 | $52k | 0.2% | Plan not stated | SEC |
| Jul 8, 2022 | Grant Papanek Julie | Director | Form 4 sale | 1,242 | $25k | 0.3% | Plan not stated | SEC |
| Jul 8, 2022 | York Charles N II | COO, CFO and Secretary | Form 4 sale | 1,416 | $28k | 0.4% | Plan not stated | SEC |
| Jul 8, 2022 | Bender Jeremy | Chief Executive Officer | Form 4 sale | 1,795 | $36k | 0.1% | Plan not stated | SEC |
| Jul 5, 2022 | York Charles N II | COO, CFO and Secretary | Form 4 sale | 2,279 | $46k | 0.7% | Plan not stated | SEC |
| Jul 5, 2022 | Grant Papanek Julie | Director | Form 4 sale | 1,800 | $36k | 0.4% | Plan not stated | SEC |
| Jul 5, 2022 | Bender Jeremy | Chief Executive Officer | Form 4 sale | 2,603 | $52k | 0.2% | Plan not stated | SEC |
| Jul 1, 2022 | Blackman Samuel C. | Chief Medical Officer | Form 4 sale | 10,000 | $187k | 0.8% | Plan not stated | SEC |
| Jun 15, 2022 | Blackman Samuel C. | Chief Medical Officer | Form 4 sale | 50,000 | $813k | 3.7% | Plan not stated | SEC |
| Jan 3, 2022 | Blackman Samuel C. | Chief Medical Officer | Form 4 sale | 10,000 | $171k | 0.7% | Plan not stated | SEC |
| Dec 8, 2021 | Takeda Pharmaceutical Co Ltd | 10% owner | Form 4 sale | 297,273 | $5.5M | 4.6% | Plan not stated | SEC |
| Dec 6, 2021 | Takeda Ventures, Inc. | 10% owner | Form 4 sale | 110,209 | $2M | 1.7% | Plan not stated | SEC |
| Dec 1, 2021 | Blackman Samuel C. | Chief Medical Officer | Form 4 sale | 10,000 | $172k | 0.7% | Plan not stated | SEC |